These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28087988)

  • 21. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
    Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H
    Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
    BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.
    Koh YW; Chun SM; Park YS; Song JS; Lee GK; Khang SK; Jang SJ
    Tumour Biol; 2016 Aug; 37(8):10675-84. PubMed ID: 26867769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Cha Y; Kim KJ; Han SW; Rhee YY; Bae JM; Wen X; Cho NY; Lee DW; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
    Br J Cancer; 2016 Jul; 115(2):164-71. PubMed ID: 27310704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer.
    Tanaka H; Deng G; Matsuzaki K; Kakar S; Kim GE; Miura S; Sleisenger MH; Kim YS
    Int J Cancer; 2006 Jun; 118(11):2765-71. PubMed ID: 16381005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.
    Wang J; Deng Z; Lang X; Jiang J; Xie K; Lu S; Hu Q; Huo Y; Xiong X; Zhu N; Zhang W
    Dis Markers; 2022; 2022():4254862. PubMed ID: 36157209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.
    Messick CA; Church JM; Liu X; Ting AH; Kalady MF
    Ann Surg Oncol; 2010 Feb; 17(2):425-31. PubMed ID: 19885699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.